Amgen DeLLphi309 Recurrent Small Cell Lung Cancer - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called tarlatamab (the study drug) is a safe and effective option for people who have small cell lung cancer (SCLC) that has progressed and spread to other parts of the body.

¿Cuál es la Condición que se está estudiando?

Small Cell Lung Carcinoma (SCLC)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with SCLC
Have received at least one previous line of treatment with a platinum-based regimen
Had their disease get worse after treatment

For more information about who can join this study, please contact the study team at annemarie.peters@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (by chance) to 1 of 3 groups. Depending on your assignment, you might:

Get a dose of the study drug every 2 weeks; OR
Get a dose of the study drug every 3 weeks; OR
Get a dose of the study drug every 4 weeks

The study drug is given as an intravenous (IV) infusion through a vein. The length of time you receive the study drug will depend on how you respond to it.